Amrutanjan Health Peer Comparison

NSE: AMRUTANJAN | BSE: 590006

₹505.45

₹-1.90 (-0.37%)

As on 04-Sep-2026 15:59IST

Market cap

₹1,464 Cr

Revenue (TTM)

₹511 Cr

P/E Ratio

27.1

P/B Ratio

3.9

Div. Yield

1 %

Edit

	Amrutanjan Health	JB Chemicals	Caplin Point Lab	Pfizer	Shilpa Medicare
Market cap (₹ Cr)	1,464	38,731	21,361	21,107	18,873
Revenue (₹ Cr)	511	4,148	2,287	2,570	1,682
Net Profit (₹ Cr)	53.97	709.47	678.07	735.15	273.51
Net Margin (%)	10.21	16.85	28.10	26.88	16.19
RoE (%)	17.47	19.11	19.73	19.16	11.15
Price to Earnings	27.12	54.59	32.11	28.71	63.48
Price-To-Book	3.91	9.31	5.82	4.79	7.03

Income Statement (₹ Cr)

	Amrutanjan Health	JB Chemicals	Caplin Point Lab	Pfizer	Shilpa Medicare
Operating Revenue	451.82	3,917.99	1,937.47	2,281.35	1,286.43
Total Income	469.50	3,957.03	2,033.90	2,453.60	1,322.88
Total Expenditure	393.51	2,886.87	1,290.54	1,541.03	980.18
EBITDA	58.31	1,031.12	646.93	740.32	306.25
Depreciation	6.53	171.04	65.96	60.79	112.99
EBIT	51.78	860.08	580.97	679.53	193.26
Interest	0.33	11.73	0.61	8.50	75.53
Other Income	17.68	39.04	96.43	172.25	36.45
Exceptional Items	--	--	--	172.81	-30.58
Profit before Tax	69.13	887.39	676.78	1,016.09	122.33
Provision for Tax	18.30	227.81	135.69	248.49	44.04
Profit after Tax	50.83	659.58	541.09	767.60	78.29

	Amrutanjan Health	JB Chemicals	Caplin Point Lab	Pfizer	Shilpa Medicare
Shareholder's Funds	326.61	3,433.32	2,850.49	4,217.41	2,362.70
Minority Interest	--	--	35.90	--	1.04
Non-Current Liabilities	7.08	443.23	13.24	54.89	259.78
Current Liabilities	84.58	1,156.93	305.99	569.51	674.19
Total Liabilities	421.39	5,033.48	3,207.85	4,911.11	3,310.68

	Amrutanjan Health	JB Chemicals	Caplin Point Lab	Pfizer	Shilpa Medicare
Non-Current Assets	127.61	2,586.15	1,071.67	1,328.96	2,313.20
Current Assets	290.67	2,447.33	2,133.95	3,512.85	984.51
Total Assets	421.39	5,033.48	3,207.85	4,911.11	3,310.68
Total Debt*	0.00	13.80	0.55	2.50	586.37
Net Current Assets	206.09	1,290.40	1,827.96	2,943.34	310.32
Contingent Liabilities	15.77	131.94	0.64	363.79	76.22

	Amrutanjan Health	JB Chemicals	Caplin Point Lab	Pfizer	Shilpa Medicare
Cash From Operating Activities	50.90	902.45	432.37	659.75	132.27
Cash Flow from Investing Activities	-30.97	-295.90	-334.73	-71.34	-199.13
Cash from Financing Activities	-13.49	-579.67	-38.32	-205.34	62.65
Net Cash Inflow / Outflow	6.44	26.88	59.32	383.07	-4.21

	Amrutanjan Health	JB Chemicals	Caplin Point Lab	Pfizer	Shilpa Medicare
ROCE (%)	22.58	26.73	26.22	26.21	6.95
ROE (%)	16.53	21.81	21.72	19.65	3.75
ROA (%)	13.00	13.58	18.37	17.03	2.45
EBIT Margin (%)	16.82	27.31	38.37	40.00	26.64
Net Margin (%)	10.83	16.67	26.60	31.28	5.92
Cash Profit Margin (%)	12.70	20.46	31.33	34.70	14.87

	Amrutanjan Health	JB Chemicals	Caplin Point Lab	Pfizer	Shilpa Medicare
Revenue Growth (%)	7.26	12.45	14.37	4.02	11.71
EBIT Growth (%)	11.33	14.56	20.21	11.86	35.64
Net Profit Growth (%)	13.03	19.35	17.27	39.23	145.00
EPS Growth (%)	13.04	18.98	17.25	39.23	118.00
Book Value Growth (%)	12.91	17.31	23.77	17.30	30.63

	Amrutanjan Health	JB Chemicals	Caplin Point Lab	Pfizer	Shilpa Medicare
Price / Earnings	36.67	38.29	28.38	23.86	41.41
Price / Book Value	5.72	7.73	5.52	4.34	2.74
Dividend Yield (%)	0.71	0.96	0.30	4.12	0.15
EV/EBITDA	23.44	23.49	19.78	17.01	20.55
Market Cap (₹ Cr)	1,864.33	25,253.79	15,219.80	18,318.10	6,484.12

	Amrutanjan Health	JB Chemicals	Caplin Point Lab	Pfizer	Shilpa Medicare
Debt to Equity	0.00	0.00	0.00	0.00	0.25
Short term debt to equity ratio	--	0.00	0.00	0.00	0.13
Current Ratio	3.44	2.12	6.97	6.17	1.46
Quick Ratio	3.11	1.66	5.88	5.33	0.94
Interest Coverage	213.00	76.66	1,110.48	120.54	2.62

	Amrutanjan Health	JB Chemicals	Caplin Point Lab	Pfizer	Shilpa Medicare
Debtors to sales (%)	12.35	20.81	32.65	8.46	34.26
Asset Turnover	1.16	0.84	0.66	0.53	0.40
Receivable days	41.89	67.54	110.70	29.10	118.15
Inventory Days	22.69	46.37	65.86	69.53	98.29
Payable days	102.13	106.33	105.88	76.77	128.16
Cash Conversion Cycle	-37.55	7.58	70.68	21.86	88.28

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.